Research suggests that institutions limit the extent to which efficient policies to reduce greenhouse gas emissions are likely to be adopted.

On April 5, 2012, the President signed into law the Jumpstart Our Business Startups (JOBS) Act, which passed by a large bipartisan majority in the Congress. The Act is designed to facilitate the equity funding of new companies. Recent research has documented that from 1980 through the 2008-09 recession new companies have been main drivers of job creation in the United States. 

Drug shortages, drug costs, the questionable quality of over-the-counter medicines: myriad issues have developed in pharmaceuticals in an era of enhanced regulatory efforts, rising healthcare costs and a global economy in which drug components are manufactured around the world.

This presentation covers the impact pharmaceutical price controls have on drug research and development.

Given the newness, apparent cost, and controversies surrounding Section 404, this regulation would be a worthwhile project for data collection in order to undertake regulatory review.

Secretary Geithner argued that we have forgotten the reasons that the Dodd-Frank Act was necessary, and that's why the act has become so controversial. What the secretary seems to have missed is that we have learned a lot in the intervening years. The administration's rush to judgment on the financial crisis is a case study in why it would have been worthwhile to wait for the facts.

Until government price controls are lifted, the makers of generics will be unable to cover their production costs.

Under the Dodd-Frank financial-reform law, large nonbank firms may be declared systemically important because their failure will cause a systemic breakdown. In effect, this amounts to a government statement that these firms are too big to fail.